ReviewCardiology research and practice2017
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.
Review in Cardiology research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Clinical and Genetic Factors Associated with Multivessel Coronary Artery Disease: A Cross-Sectional Study of CYP2C19 Polymorphisms and Metabolic Comorbidities.International journal of general medicine · 2026Article
- CYP2C19 intermediate and poor metabolizer statuses may be associated with coronary atherosclerosis among patients with type 2 diabetes mellitus.Frontiers in medicine · 2026Article
- CYP2C19 Genetic Variants Associated with Clopidogrel Resistance and Major Adverse Cardiovascular Events in Vietnamese Patients Undergoing Percutaneous Coronary Intervention.Cardiovascular & hematological disorders drug targets · 2026Article
- Advances in the Clinical Use of Clopidogrel: A Review of Individualized Treatment Strategies and Monitoring Optimization Based on Genetic Polymorphisms.Pharmacogenomics and personalized medicine · 2025Review
- Real-time platelet P2YActa pharmaceutica Sinica. B · 2025Article
- CYP2C19 loss-of-function variants are independent risk factors for premature cerebral infarction: a hospital based retrospective study.BMC cardiovascular disorders · 2024Article
- The association between abcb1 gene polymorphism and clopidogrel response variability in stroke ischemic: a cross sectional study.BMC neurology · 2024Article
- Article
- Co-Existence ofBalkan journal of medical genetics : BJMG · 2023Article
- Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients.Vascular health and risk management · 2023Article
- Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carryingJournal of thoracic disease · 2022Article
- Relationship between platelet aggregation and stroke risk after percutaneous coronary intervention: a PENDULUM analysis.Heart and vessels · 2022Article
- Platelet aggregometry for hip fracture surgery in patients treated with clopidogrel: a pilot study.Journal of clinical monitoring and computing · 2022Observational
- The Therapeutic Potential of Anticoagulation in Organ Fibrosis.Frontiers in medicine · 2022Review
- A Pharmacogenetic Study ofJournal of personalized medicine · 2021Article
- Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.European journal of clinical pharmacology · 2021Article
- The Role of Platelets in the Stimulation of Neuronal Synaptic Plasticity, Electric Activity, and Oxidative Phosphorylation: Possibilities for New Therapy of Neurodegenerative Diseases.Frontiers in cellular neuroscience · 2021Article
- Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy.Pharmacology research & perspectives · 2020Review
- Integration analysis of metabolites and single nucleotide polymorphisms improves the prediction of drug response of celecoxib.Metabolomics : Official journal of the Metabolomic Society · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular events. Although many genetic and nongenetic factors are known, great portion of clopidogrel variable platelets reactivity remain unexplained which challenges the personalization of clopidogrel therapy. Current methods for clopidogrel personalization include
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.